Skip to main content
SpringerLink
Log in

Steroidal and Nonsteroidal Anti-inflammatory Agents for Ocular Use

  • Chapter
  • First Online:
Pharmacology of Ocular Therapeutics

  • 1653 Accesses

Abstract

Multiple factors cause ocular inflammation in various anatomical regions of the eye. Such inflammations are usually tackled with limited symptomatic treatment modalities. The poor prognosis of or long-standing ocular inflammation can even culminate into permanent loss of vision. Ocular inflammation can be majorly divided into infections and non-infections conditions. This chapter deals with the various ocular anti-inflammatory agents used in conditions like uveitis, ocular manifestations of Behchets disease, diabetic retinopathy and allergic conditions leading to ocular surface inflammations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abelson MB, Greiner JV. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20:1953–8.

    Article  PubMed  CAS  Google Scholar 

  • Abelson MB, Schaefer K. Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38:S115–32.

    Article  Google Scholar 

  • Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302.

    Article  PubMed  CAS  Google Scholar 

  • Abelson MB, Yamamoto GK, Allansmith MR. Effects of ocular decongestants. Arch Ophthalmol. 1980;98(5):856–8.

    Article  PubMed  CAS  Google Scholar 

  • Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012;32:507–17.

    Article  PubMed Central  PubMed  Google Scholar 

  • Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute controlled trial. Clin Ther. 2005;27:1392–402.

    Article  PubMed  CAS  Google Scholar 

  • Brodsky M, Berger WE, Butrus S, Epstein AB, Irkec M. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen challenge model. Eye Contact Lens. 2003;29:113–6.

    Article  PubMed  Google Scholar 

  • Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther. 2003;25:1975–87.

    Article  PubMed  CAS  Google Scholar 

  • D’Arienzo PA, Leonardi A, Bensch G. Randomized, doublemasked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther. 2002;24:409–16.

    Article  PubMed  Google Scholar 

  • del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3–12.

    PubMed  Google Scholar 

  • Duzman E, Warman A, Warman R. Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis. Ann Ophthalmol. 1986;18(1):28–31.

    PubMed  CAS  Google Scholar 

  • Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol. 2008;154:1166–81.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Geltzer A, Turalba A, Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2013;1: CD005022. doi:10.1002/14651858.CD005022.pub3.

  • Grossmann EE, Lehman RH. Ophthalmic use of tyzine; a clinical study of this new vasoconstrictor. Am J Ophthalmol. 1956;42(1):121–3.

    Article  PubMed  CAS  Google Scholar 

  • Karampetsou MP, Liossis SN, Sfikakis PP. TNF-a antagonists beyond approved indications: stories of success and prospects for the future. Q J Med. 2010;103:917–28.

    Article  CAS  Google Scholar 

  • KaÅ¡telan S, Tomi MT, Gverovic Antunica A, Salopek Rabati J, Ljubi S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm. 2013:Article ID 213130, 8.

    Google Scholar 

  • Kidd M, McKenzie SH, Steven I, Cooper C, Lanz R. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol. 2003;87:1206–11.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Kubo DJ, Wing TW, Polse KA, Jauregui MJ. Mydriatic effects using low concentrations of phenylephrine hydrochloride. J Am Optom Assoc. 1975;46(8):817–22.

    PubMed  CAS  Google Scholar 

  • Lanier BQ, Finegold I, D’Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20:1227–33.

    Article  PubMed  CAS  Google Scholar 

  • Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011;16(2):309–22.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Leite-de-Moraes MC, Diem S, Michel ML, Ohtsu H, Thurmond RL, Schneider E, Dy M. Cutting edge: histamine receptor H4 activation positively regulates in vivo IL-4 and IFN-gamma production by invariant NKT cells. J Immunol. 2009;182:1233–6.

    Article  PubMed  CAS  Google Scholar 

  • Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Curr Med Res Opin. 2004;20:1167–73.

    Article  PubMed  CAS  Google Scholar 

  • Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489–98.

    Article  PubMed  CAS  Google Scholar 

  • Majumdar S, Srirangam R. Potential of the bioflavonoids in the prevention/treatment of ocular disorders. J Pharm Pharmacol. 2010;62(8):951–65.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Menger HC. New ophthalmic decongestant, tetrahydrozoline hydrochloride; clinical use in 1,156 patients with conjunctival irritation. J Am Med Assoc. 1959;170(2):178–9.

    Article  PubMed  CAS  Google Scholar 

  • Nayak BK, Kishore K, Gupta SK. Evaluation of oxymetazoline and naphazoline in benign red eyes: a double blind comparative clinical trial. Indian J Ophthalmol. 1987;35(4):190–3.

    PubMed  CAS  Google Scholar 

  • Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics: Targets and Therapy. 2014;8:67–81.

    Google Scholar 

  • Pescosolido N, Giannotti R, Plateroti AM, Pascarella A, Nebbioso M. Curcumin: therapeutical potential in ophthalmology. Planta Med. 2014;80:249–54.

    PubMed  CAS  Google Scholar 

  • Ratner P, Falques M, Chuecos F, Esbri R, Gispert J, Peris F, Luria X, Rosales MJ. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol. 2005;138:312–8.

    Article  PubMed  CAS  Google Scholar 

  • Rybiczka R, Mauracher E. Oxymetazoline ophthalmic solution versus naphazoline solution in non-infectious conjunctivitis. Pharmatherapeutica. 1983;3(6):376–81.

    PubMed  CAS  Google Scholar 

  • Saravanan C, Bharti SK, Jaggi S, Singh SK. Histamine H(4) receptor: a novel target for inflammation therapy. Mini Rev Med Chem. 2011;11(2):143–58.

    Article  PubMed  CAS  Google Scholar 

  • Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther. 2001;23:1272–80.

    Article  PubMed  CAS  Google Scholar 

  • Spangler DL, Abelson MB, Ober A, Gotnes PJ. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther. 2003;25:2245–67.

    Article  PubMed  CAS  Google Scholar 

  • Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov. 2008;7:41–53.

    Article  PubMed  CAS  Google Scholar 

  • Verin P, Easty DL, Secchi A, Ciprandi G, Partouche P, Nemeth-Wasmer G, Brancato R, Harrisberg CJ, Estivin-Ebrardt C, Coster DJ, Apel AJ, Coroneo MT, Knorr M, Carmichael TR, Kent-Smith BT, Abrantes P, Leonardi A, Cerqueti PM, Modorati G, Martinez M. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol. 2001;131:691–8.

    Article  PubMed  CAS  Google Scholar 

  • Verma S, Kroeker KI, Fedorak RN. Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature. BMC Gastroenterol. 2013;13:59.

    Article  PubMed Central  PubMed  Google Scholar 

  • Yokota E, Kuyama S, Sugimoto Y, Ogawa M, Kamei C. Participation of histamine H3 receptors in experimental allergic rhinitis of mice. J Pharmacol Sci. 2008;108:206–11.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi, India

    Rajani Mathur PhD

  2. University of Delhi, New Delhi, India

    Rajani Mathur PhD

  3. Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Selangor Darul Ehsan, Malaysia

    Renu Agarwal PhD

Authors
  1. Rajani Mathur PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renu Agarwal PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajani Mathur PhD .

Editor information

Editors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. RP Centre for Ophthalmic Sciences, New Delhi, India

    Thirumurthy Velpandian

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mathur, R., Agarwal, R. (2016). Steroidal and Nonsteroidal Anti-inflammatory Agents for Ocular Use. In: Velpandian, T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham. https://doi.org/10.1007/978-3-319-25498-2_8

Download citation

Publish with us

Policies and ethics

Search

Navigation